Blog
RSS FeedPosted by Michael Wonder on 18 Jun 2018
ICER to assess canakinumab for atherosclerosis
18 June 2018 - Review will be subject of January Midwest CEPAC meeting; open Input now being accepted until 5 ...
Posted by Michael Wonder on 16 Jun 2018
ICER report questions the adequacy of evidence on overall health benefit of elagolix given limitations of information on safety and limited evidence comparing to other treatment options
15 June 2018 - The emerging drug may be cost-effective compared to no treatment if priced in line with analyst ...
Posted by Michael Wonder on 12 Jun 2018
ICER's updated assessment of new targeted therapies for plaque psoriasis notes minor distinctions in effectiveness, while recent price hikes have made entire drug class less cost-effective
12 June 2018 - Value-based price benchmarks for new IL-23 agents range from $25,000-$42,000 per year, which would require a discount ...
Posted by Michael Wonder on 07 Jun 2018
ICER's final report on CFTR modulators for cystic fibrosis calls for manufacturer restraint and increased transparency in pricing decisions
7 June 2018 - Pricing overreach harms people with cystic fibrosis and threatens the health care system's ability to support future ...
Posted by Michael Wonder on 01 Jun 2018
New analysis shows using ICER’s value assessments would limit access to life-saving medicines in Medicare Part B
31 May 2018 - 62 to 93% of Medicare Part B beneficiaries with serious, complex conditions could lose access to their ...
Posted by Michael Wonder on 31 May 2018
ICER finds price of erenumab aligns with clinical benefit in patients for whom other therapies have failed to prevent migraines
31 May 2018 - Clinical benefits similar to other new CGRP inhibitors included in review. ...
Posted by Michael Wonder on 15 May 2018
ICER posts draft scoping document on biologic treatments for asthma
15 May 2018 - Document open to public comment until 5 June 2018. ...
Posted by Michael Wonder on 15 May 2018
Americans thought they would get a PHARMAC from Trump
15 May 2018 - If New Zealand was showing any interest in a bilateral trade agreement with the United States, ...
Posted by Michael Wonder on 14 May 2018
ISPOR launches Center for Health Technology Assessment
14 May 2018 - New website offers comprehensive repository of resources and tools. ...
Posted by Michael Wonder on 09 May 2018
Evaluating and valuing drugs for rare conditions: no easy answers
9 May 2018 - We find ourselves in an era of unprecedented growth in the development and use of so-called “orphan” ...
Posted by Michael Wonder on 05 May 2018
Watchdog says Vertex cystic fibrosis drugs are not cost effective, but company calls analysis a ‘sham’
4 May 2018 - The oldest Vertex drug for cystic fibrosis, Kalydeco, lists for $311,000, while the newer treatment Orkambi lists ...
Posted by Michael Wonder on 05 May 2018
ICER releases draft evidence report on elagolix for endometriosis
4 May 2018 - Public comment period now open until 31 May; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 01 May 2018
The ICER appoints new members to each of its three independent evidence appraisal councils
1 May 2018 - New members bring expertise in broad range of perspectives, including health policy, economics, and clinical practice. ...
Posted by Michael Wonder on 27 Apr 2018
ICER releases draft condition update report on treatments for plaque psoriasis
27 April 2018 - Public comment period now open until 25 May; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 27 Apr 2018
ICER posts draft scoping document on medication-assisted treatments for opioid use disorder
26 April 2018 - Document open to public comment until 16 May 2018; report expected to review buprenorphine implant, extended-release ...